Summary:
- Mental health continues to be a leading clinical focus for digital health investors.
- Wysa, maker of an AI-backed chatbot that aims to help users work though concerns like anxiety, stress and low mood, recently announced a $20 million Series B funding raise, not long after the startup received FDA Breakthrough Device Designation to use its tool to help adults with chronic musculoskeletal pain.
- Ramakant Vempati, the company’s Cofounder and President, sat down with MobiHealthNews to discuss how the chatbot works, the guardrails Wysa uses to monitor safety and quality, and what’s next after its latest funding round.
